NEW YORK, Aug. 20 – Venture capital investment in US biotechnology companies, which include genomic and bioinformatics firms, has increased by $100 million to $1.1 billion since the beginning of the year, even as overall venture financing plunged by 58 percent to $25 billion, according to a recent analysis.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.